This article is more than 5 years old. Information may no longer be current.
Bimatoprost SR NDA acceptance tops July glaucoma news
Click Here to Manage Email Alerts
July’s glaucoma news included updates on trial enrollments and study results.
Here are the top five glaucoma-related articles on Healio.com/OSN during the month:
FDA accepts application for Bimatoprost Sustained-Release
Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months. Read more.
iSTAR’s MINIject shows positive 18-month results
Nearly two-third of patients who received the MINIject device, which reduces IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space, were able to cease eye drop usage. Read more.
Netarsudil trial completes enrollment in Japan
The prospective, double-masked, multicenter, placebo-controlled, parallel group trial includes 215 patients randomly assigned to one of four treatment arms: netarsudil 0.01%, 0.02% or 0.04% or placebo, administered once daily in the evening. Read more.
PolyActiva completes enrollment in glaucoma implant trial
The study is evaluating the safety and tolerability of the Latanoprost FA SR implant, which is designed to provide a constant daily dose of latanoprost free acid for at least 30 weeks. Read more.
Nicox completes enrollment in NCX 470 trial
Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Read more.